Risankizumab Bests Other Biologics in Real-world Psoriasis Study
Risankizumab (Skyrizi, AbbVie) achieved significantly higher durable clinical responses in real-world practice compared to a BioCohort, including other biologics, for the treatment of moderate-to-severe psoriasis, according to a 148-week interim analysis of the ongoing VALUE trial presented at the World Psoriasis & Psoriatic Arthritis (IFPA) Conference in Stockholm, Sweden. In the post-marketing study of more […]